The company had a big announcement this week from the company that could be catalytic…
As part of its restructuring plans to unlock value for shareholders, SPRC announced that it has appointed a new Vice President of Strategy and Business Development, Mr. Yaki Baranes, to structure business strategies and facilitate identifying new business opportunities.
Mr. Baranes works with start-up companies in shaping their business plans and supporting their capital raising rounds as well as identifying new business opportunities.
This specialty clinical-stage pharmaceutical company is already led by an experienced team of senior executives and scientists and adding Mr. Baranes to the board could be exponential for further growth.
Currently, SPRC has a "STRONG BUY" rating from Investing.com.
The legal MJ industry is expected to expand exponentially in the coming years and savvy investors are seeking to profit. Just last October, President Biden announced MJ reforms, which could be the steppingstone for the U.S. to decriminalize the plant on a federal level.
In the meantime, as more states in the U.S. and countries decriminalize or legalize the plant and/or its components, there is a growing opportunity on Wall Street to enter the space.
This highlights even more why SciSparc (SPRC) a small-cap NASDAQ biotech company trading under $1 a share, could have astronomical upside potential!
SPRC has been climbing the ranks of the pharma industry and is revolutionizing the way the world approaches modern medicine!
https://scisparc.com/
SciSparc Ltd.
NASDAQ: SPRC
A Robust IP Portfolio
Repurposing previously approved compounds qualifies SPRC to take advantage of the FDA's 505 (b)(2) application protocol. This potentially means lower risk, and an expedited development timeline. The result is a robust pipeline of product candidates well positioned to create significant shareholder value into the future.
SciSparc has built an intellectual property portfolio which currently comprises three granted U.S. patents and pending patent applications in six families, all focused on disorders of the central nervous system.
Currently, the company's drug candidates are designed to treat Tourette Syndrome, Autism Spectrum Disorder, Epilepsy, Obstructive Sleep Apnea, Alzheimer's Disease and Agitation, and Pain.
The company's research and development efforts are focused on creating a proprietary and unique combination of products, some available already in the market (CannAmide™), products in the accelerated regulatory path of 505 (b)(2) application (SCI-110, SCI-210) and
products that constitute a new chemical entity (SCI-160) in order to bring different products to market at different timelines and potentially enable them to generate immediate revenues for the company.
Joint Venture Agreement with MitoCareX Bio Ltd.
Not long ago, SPRC announced completion of its previously announced joint venture agreement to focus on the discovery and development of potential drugs for cancers and other life-threatening conditions, with MitoCareX Bio Ltd., an Israeli corporation.
MitoCareX Bio will focus on investigating mitochondrial carriers, transport proteins crucial for cell viability.
Because of mitochondrial carriers' significant role in transporting necessary metabolites for cell functioning across the inner mitochondrial membranes, the company believes various life-threatening conditions, such as cancers and rare mitochondrial diseases, might be treated by regulating the function of mitochondrial carriers!
In humans, the mitochondrial carrier family (Solute Carrier Family 25, SLC25) consists of 53 members and is the largest solute transporter.
Details of the JV agreement can be found HERE.
The joint venture MitoCareX Bio, focuses on the discovery and development of potential drugs for cancers, rare diseases and other life-threatening conditions, succeeded to develop its core algorithm for allowing the generation of reliable 3D comparative models of human SLC25A mitochondrial carrier proteins - promising transporting targets for innovating therapies.
Trustable 3D models of mitochondrial transporters are a valuable tool for the discovery of anti-cancer drugs to help drug producers develop more effective and targeted therapies for cancer.
The human mitochondrial carrier family (SLC25A protein family) is the largest group of solute carriers transporting a variety of metabolites, amino acids, nucleotides, and cofactors across the highly selective inner mitochondrial membrane. Consisting of 53 members, transporters of this family are extensively shown to be involved in different types of malignancies such as: cervical, prostate, hepatocellular carcinoma, and breast cancer, among others.
However, a major challenge for drug discovery in the field is the very limited amount of solved 3D protein structures (e.g., by x-ray crystallography) that can often ignite computer aided drug discovery campaigns. In addition, these proteins have different functional conformations that may be challenging to be correctly predicted with current machine learning (ML) or AI-based systems, without ad-hoc guidance.
To address this challenge, MitoCareX Bio has developed MITOLINE™ - an algorithm used by the company to translate its knowledge concerning specific "hot-spots" within key mitochondrial carriers' amino acid sequences for the generation of reliable 3D comparative models.
According to the company, the generated MITOLINE™ based 3D comparative models of mitochondrial carriers can be used for the study of ligand binding, substrate translocation mechanism, and for the characterization of yet uncharacterized mitochondrial carriers.
Joint Pre-Clinical Trial with Clearmind Medicine Inc.
SPRC has a joint pre-clinical trial with Clearmind Medicine Inc., (CSE: CMND), (OTC: CMNDF), (FSE: CWY0), a psychedelic pharmaceutical company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems.
The trial has already tested the proprietary combination of SPRC's CannAmide™ with Clearmind's psychedelic molecule, MEAI, for alcohol consumption.
The results of this ground-breaking research show potential for the first dedicated cocaine addiction treatment! You can read about the trial HERE.
As part of its ongoing collaboration with Clearmind Medicine Inc., an additional provisional patent application was filed by Clearmind with the United States Patent and Trademark Office ("USPTO").
The latest patent application refers to the protection of the unique combination of MEAI and SciSparc's Palmitoylethanolamide ("PEA") for the treatment of depression.
Under this collaboration, three other patent applications have been filed by Clearmind with the USPTO for the combination of SciSparc's PEA with Clearmind's MEAI compound (5-methoxy-2-aminoindane) for the treatment of alcohol use disorder, treatment of cocaine addiction and treatment of obesity and its related metabolic disorders.
An additional six patent applications have been filed for the combination of SciSparc's PEA and lysergic acid diethylamide (LSD), psilocybin, and N,N-dimethyltryptamine (DMT), 3,4 methylenedioxymethamphetamine (MDMA), ibogaine and ketamine.
In Summary…
While the usage of cannabis has been popular in recent years, it's only very recently that we are discovering the rare cannabinoid potential.
Early studies have shown the exciting efficacy of cannabinoids against a large variety of diseases. For example, preclinical and clinical studies have suggested a potential value for CBD in some neuropsychiatric disorders, including epilepsy, anxiety, and schizophrenia.
Psychedelics have also become an increasingly popular area for medical research and studies. A report by Market Digits estimates that the sector could be worth more than $10 billion by 2027, up from $4.75 billion in 2020!
With so many people around the world suffering from conditions that have no known cure, it's become vital that research and more is done to help these people and the symptoms they endure as a result of these conditions.
With strong leadership, exciting joint ventures, as well as a growing $4M+ market cap SciSparc Ltd. (NASDAQ: SPRC) looks positioned to shine bright in the market and could be at SUPREME VALUE right now.
This may be one of the most exciting small-cap biotech stocks of 2023!
START YOUR RESEARCH!
No comments:
Post a Comment